{"news_desk": "Business", "print_page": null, "section_name": "Business Day", "subsection_name": "DealBook", "byline": {"original": "By ROBERT CYRAN", "person": [{"rank": 1, "role": "reported", "firstname": "Robert", "organization": "", "lastname": "CYRAN"}]}, "abstract": null, "type_of_material": "News", "word_count": "365", "lead_paragraph": "The $39 billion drug company only helped confirm some investor fears about its dealings involving Philidor Rx Services.", "pub_date": "2015-10-27T00:00:00Z", "document_type": "article", "slideshow_credits": null, "headline": {"main": "In Trying to Explain Itself, Valeant Muddies the Water", "content_kicker": "Breakingviews", "kicker": "Breakingviews"}, "snippet": "The $39 billion drug company only helped confirm some investor fears about its dealings involving Philidor Rx Services.", "multimedia": [], "web_url": "http://www.nytimes.com/2015/10/27/business/dealbook/in-trying-to-explain-itself-valeant-muddies-the-water.html", "keywords": [{"rank": "1", "is_major": "N", "value": "Drugs (Pharmaceuticals)", "name": "subject"}, {"rank": "2", "is_major": "N", "value": "Valeant Pharmaceuticals International Inc", "name": "organizations"}], "blog": [], "_id": "562e8b0038f0d82f94187c8b", "source": "The New York Times"}